Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.

Detaljer

Författare
  • Andreas Hillarp
  • Kerstin M Gustafsson
  • Lars Faxälv
  • Karin Strandberg
  • Fariba Baghaei
  • Inger Fagerberg Blixter
  • Maria Berndtsson
  • Tomas L Lindahl
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Kardiologi
Originalspråkengelska
Sidor (från-till)1545-1553
TidskriftJournal of Thrombosis and Haemostasis
Volym12
Utgivningsnummer9
StatusPublished - 2014
PublikationskategoriForskning
Peer review utfördJa